- Azathioprine
-
- $0.00 / 1kg
-
2024-04-15
- CAS:446-86-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
- Azathioprine
-
- $0.00 / 1KG
-
2023-09-06
- CAS:446-86-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500000kg
- Azathioprine
-
- $5.00 / 1KG
-
2023-04-27
- CAS:446-86-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 10000kg
|
| | Azathioprine Chemical Properties |
| Melting point | 243-244°C | | Boiling point | 521.0±60.0 °C(Predicted) | | density | 1.5379 (rough estimate) | | refractive index | 1.7400 (estimate) | | storage temp. | 2-8°C | | solubility | Soluble in Dichloromethane and dimethyl sulfoxide. | | pka | 8.2(at 25℃) | | color | Pale-yellow crystals from Me2CO (aq) | | Water Solubility | <0.1 g/100 mL at 23 ºC | | Merck | 14,902 | | BCS Class | 4 | | Stability: | Stable. Incompatible with strong oxidizing agents, strong bases. | | InChIKey | LMEKQMALGUDUQG-UHFFFAOYSA-N | | CAS DataBase Reference | 446-86-6(CAS DataBase Reference) | | IARC | 1 (Vol. 26, Sup 7, 100A) 2012 | | EPA Substance Registry System | Azathioprine (446-86-6) |
| | Azathioprine Usage And Synthesis |
| Application in Particular Diseases | In Rheumatic Arthritis:
Azathioprine is a purine analog that is converted to 6-mercaptopurine and is thought to interfere with DNA and RNA synthesis. Antirheumatic effects may be seen in 3 to 4 weeks. It should be discontinued if no response is observed after 12 weeks at maximal doses. Its major adverse effects are bone marrow suppression (leukopenia, macrocytic anemia, thrombocytopenia, pancytopenia), stomatitis, GI intolerance, infections, drug fever, hepatotoxicity, and oncogenic potential.
| | Description | This immunosuppressive and antineoplastic drug is
derived from 6-mercaptopurine. It caused occupational
dermatitis in a pharmaceutical worker, reconditioner
of old tablet packaging machines and in a production
mechanic, working in packaging for a pharmaceutical
company. | | Chemical Properties | Yellow Solid | | Chemical Properties | Azathioprine is a complex heterocyclic
compound which forms pale yellow crystals. | | Originator | Imuran,Wellcome,UK,1964 | | Uses | Azathioprine is an immunosuppressive purine antimetabolite. The mechanism of action of azathioprine is as a nucleic acid synthesis inhibitor. It has shown promise in treatment of alopecia areata (autoimmune hair loss), with no difference in effectiveness between genders. | | Uses | immunosuppressant, antineoplastic, antirheumatic | | Uses | An immunosuppressive antimetabolite. Also active as disease modifying antirheumatic drug (DMARD). Azathioprine is a purine analog with immunosuppressive effects. | | Definition | ChEBI: A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and a
ter organ transplantation and also for treatment of Crohn's didease and MS. | | Indications | Azathioprine (Imuran) is a cytotoxic agent that preferentially
destroys any rapidly dividing cell. Since immunologically
competent cells are generally rapidly dividing
cells, azathioprine is very effective as an
immunosuppressive drug. Unfortunately, any cell that is
replicating is a target for this action. This lack of specificity
leads to serious side effects.
Azathioprine, in combination with corticosteroids,
has historically been used more widely than any other
drug in immunosuppressive therapy. It is classified as a
purine antimetabolite and is a derivative of 6-mercaptopurine. | | Manufacturing Process | N,N'-Dimethyloxaldiamide is reacted with PCl5, to give 4-chloro-1-methyl
imidazole. This is nitrated with HNO3 to give 5-nitro-1-methyl-4-
chloroimidazole. Then, a mixture of 4.6 grams of anhydrous 6-
mercaptopurine, 5 grams of 1-methyl-4-chloro-5-nitroimidazole and 2.5 grams
of anhydrous sodium acetate in 100 ml of dry dimethyl sulfoxide was heated
at 100°C for 7 hours.
After standing overnight at room temperature, the mixture was poured into
200 ml of cold water and the yellow precipitate of 6-(1'-methyl-4'-nitro-5'-
imidazolyl)mercaptopurine (7.0 grams) collected. After recrystallization from
50% aqueous acetone, the product melted at 243-244°C, dec., and had an UV
spectrum with λ maximum = 280 nm at pH 1 and λ max. = 285 nm at pH 11. | | Brand name | Imuran (Promethus). | | Therapeutic Function | Immunosuppressive | | General Description | Pale yellow crystals or yellowish powder. Decomposes at 243-244°C. Used for the treatment of rheumatoid arthritis. A known carcinogen. | | Air & Water Reactions | Sensitive to oxidation in the air. Insoluble in water. | | Reactivity Profile | Azathioprine may react exothermically with acids. Incompatible with isocyanates, peroxides, phenols, epoxides, anhydrides, and acid halides. Hydrolyzed by strongly basic solutions . May react with strong reducing agents to generate flammable gaseous hydrogen or hydrogen sulfide. | | Hazard | Confirmed carcinogen. | | Fire Hazard | Flash point data for Azathioprine are not available. Azathioprine is probably combustible. | | Contact allergens | This immunosuppressive and antineoplastic drug is
derived from 6-mercaptopurine. It caused allergic contact
dermatitis in a mother crushing tablets for her leukemic
son, and occupational dermatitis in a pharmaceutical
reconditioner of old tablet packaging machines, and in a
production mechanic working in packaging for a pharmaceutical
company. | | Biochem/physiol Actions | Has shown promise in treatment of alopecia areata (autoimmune hair loss), with no difference in effectiveness between genders. | | Mechanism of action | Azathioprine is a phase-specific drug that is toxic to
cells during nucleic acid synthesis. Phase-specific drugs
are toxic during a specific phase of the mitotic cycle,
usually the S-phase, when DNA synthesis is occurring,
as opposed to cycle-specific drugs that kill both cycling
and intermitotic cells.
Azathioprine is converted in vivo to thioinosinic
acid, which competitively inhibits the synthesis of inosinic
acid, the precursor to adenylic acid and guanylic
acid. In this way, azathioprine inhibits DNA synthesis
and therefore suppresses lymphocyte proliferation.This
effectively inhibits both humoral and cell-mediated immune
responses. | | Pharmacology | Azathioprine is well absorbed following oral administration,
with peak blood levels occurring within 1 to 2
hours. It is rapidly and extensively metabolized to 6-
mercaptopurine, which is further converted in the liver
and erythrocytes to a variety of metabolites, including 6-
thiouric acid. Metabolites are excreted in the urine.The
half-life of azathioprine and its metabolites in the blood
is about 5 hours. | | Clinical Use | Azathioprine is a relatively powerful antiinflammatory
agent. Although its beneficial effect in various conditions
is principally attributable to its direct immunosuppressive
action, the antiinflammatory properties of the
drug play an important role in its overall therapeutic effectiveness.
Azathioprine has been used widely in combination
with corticosteroids to inhibit rejection of organ transplants,
particularly kidney and liver allografts. However,
it is usually reserved for patients who do not respond to
cyclosporine plus corticosteroids alone.
Azathioprine also has applications in certain disorders
with autoimmune components, most commonly
rheumatoid arthritis. It is as effective as cyclophosphamide
in the treatment of Wegener’s granulomatosis.
It has largely been replaced by cyclosporine in immunosuppressive
therapy. Relative to other cytotoxic
agents, the better oral absorption of azathioprine is the
reason for its more widespread clinical use. | | Side effects | The therapeutic use of azathioprine has been limited by
the number and severity of adverse effects associated
with its administration. Bone marrow suppression resulting
in leukopenia, thrombocytopenia, or both may
occur. GI toxicity may be a problem. It is also mildly hepatotoxic.
Because of its immunosuppressive activity,
azathioprine therapy can lead to serious infections. It
has been shown to be mutagenic in animals and humans
and carcinogenic in animals. | | Safety Profile | Confirmed human
carcinogen producing bladder tumors and
leukemia. Poison by subcutaneous,
intradermal, and intraperitoneal routes.
Moderately toxic by ingestion. Human
systemic effects: liver changes,
hypermotility, diarrhea, nausea or vomiting,
increased body temperature, BP lowering,
decreased urine volume or anuria,
normocytic anemia, bone marrow changes.
An experimental teratogen. Other
experimental reproductive effects. Human
mutation data reported. When heated to
decomposition it emits very toxic fumes of
NO,xand SOx. An immunosuppressant. | | Synthesis | Azathioprine, 6-[(1-methyl-4-nitroimidazol-5-yl)thio]purine (31.2.1), is
synthesized by heteroarylation of the sulfhydrile group of 6-mercaptopurine (30.1.2.9) with
5-chloro-1-methyl-4-nitroimidazol in the presence of sodium acetate as a weak base. 
| | Potential Exposure | Azathioprine is an immunosuppressive
agent, generally used in combination with a corticosteroid
to prevent rejection following renal homotransplantations.
It also is used following transplantation of other organs.
Other uses of azathioprine include the treatment of a variety
of presumed autoimmune diseases, including rheumatoid
arthritis; ankylosing spondylitis; systemic lupus
erythematosus; dermatonyositis, periarteritis nodosa, scleroderma,
refractory thombocytopenic purpura; autoimmune
hemolytic anemia; chronic active liver disease; regional
enteritis; ulcerative colitis; various autoimmune diseases of
the eye; acute and chronic glomerulonephritis; the nephritic
syndrome; Wegener’s granulomatosis; and multiple
sclerosis. | | Veterinary Drugs and Treatments | In veterinary medicine, azathioprine is used primarily as an immunosuppressive
agent in the treatment of immune-mediated
diseases in dogs. See Doses below for more information. For autoagglutinizing
immune mediated hemolytic anemia, azathioprine is
generally recommended to start at the time of diagnosis. When used
in combination with cyclosporine, azathioprine has been used to
prevent rejection of MHC-matched renal allografts in dogs.
Although the drug can be very toxic to bone marrow in cats, it is
sometimes used to treat feline autoimmune
skin diseases. | | Drug interactions | Potentially hazardous interactions with other drugs
Allopurinol: enhances effect with increased
toxicity. Reduce azathioprine dose by 50-75% if
administered concomitantly - ideally avoid.
Antibacterials: increased risk of haematological
toxicity with co-trimoxazole.
Anticoagulants: possibly reduced anticoagulant effect
of coumarins.
Antipsychotics: avoid with clozapine.
Antivirals: myelosuppressive effects enhanced by
ribavirin.
Ciclosporin: decreased ciclosporin absorption and
bioavailability.
Cytotoxics may be additive or synergistic in
producing toxicity, particularly on the bone marrow.
Febuxostat: avoid concomitant use.
Vaccines: risk of generalised infections with live
vaccines - avoid. | | First aid | If this chemical gets into the eyes, remove anycontact lenses at once and irrigate with water or normalsaline immediately for at least 20°30 min, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts the skin, removecontaminated clothing and wash immediately with soap andwater. Seek medical attention immediately. If this chemicalhas been inhaled, remove from exposure, begin rescuebreathing (using universal precautions, including resuscitation mask) if breathing has stopped and CPR if heart actionhas stopped. Transfer promptly to a medical facility. Whenthis chemical has been swallowed, get medical attention.Give large quantities of water and induce vomiting. Do notmake an unconscious person vomit. | | Carcinogenicity | Azathioprine is known to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in humans. | | Metabolism | Azathioprine is extensively metabolised to its active moiety
mercaptopurine, which in turn is activated intracellularly
by conversion to nucleotide derivatives. Mercaptopurine
is rapidly and extensively metabolised in the liver, by
methylation, oxidation and by the formation of inorganic
sulfates. Thiol methylation is catalysed by the enzyme
thiopurine methyltransferase (TPMT). TPMT activity is
highly variable in patients because of a genetic polymorphism
in the TPMT gene. About 10% of a dose of azathioprine is
reported to be split between the sulfur and the purine ring
to give 1-methyl-4-nitro-5-thioimidazole. The proportion of
different metabolites is reported to vary between patients.
Metabolites and small amounts of unchanged azathioprine
and mercaptopurine are eliminated in the urine. | | storage | Color Code—Blue: Health Hazard/Poison: Store ina secure poison location. Prior to working with this chemicalyou should be trained on its proper handling and storage.Store in a refrigerator under an inert atmosphere. A regulated, marked area should be established where this chemicalis handled, used, or stored in compliance with OSHAStandard 1910.1045. | | Shipping | UN2811 Toxic solids, organic, n.o.s., Hazard
Class: 6.1; Labels: 6.1-Poisonous materials, Technical
Name Required. | | Incompatibilities | Incompatible with reducing agents, such
as hydrides (may cause the release of explosive gases), oxidizers
(chlorates, nitrates, peroxides, permanganates, perchlorates,
chlorine, bromine, fluorine, etc.); contact may
cause fires or explosions. Keep away from alkaline materials,
strong acids (violent exothermic reaction), strong bases. |
| | Azathioprine Preparation Products And Raw materials |
|